Leerink and Guggenheim are acting as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics announces common stock offering, no amount given
- Promising Potential of Larimar Therapeutics’ Nomlabofusp in Friedreich’s Ataxia: A Buy Rating Justified
- Positive Outlook for Larimar Therapeutics: Promising Data on Nomlabofusp and Anticipated Catalysts Drive Buy Rating
- Larimar Therapeutics’ nomlabofusp shows therapeutic potential in FA
- Promising Regulatory Progress and Market Potential for Larimar Therapeutics